Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a report published on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Trevena Price Performance

Shares of Trevena stock opened at $1.70 on Monday. The stock has a 50-day simple moving average of $3.15 and a 200-day simple moving average of $5.72. Trevena has a 52-week low of $1.13 and a 52-week high of $19.23. The firm has a market cap of $1.46 million, a price-to-earnings ratio of -0.04 and a beta of 1.08.

Trevena (NASDAQ:TRVN) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share (EPS) for the quarter. The firm had revenue of $0.28 million during the quarter. As a group, equities research analysts predict that Trevena will post -32.25 earnings per share for the current year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.